Dohj LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dohj LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 589 shares of the biopharmaceutical company’s stock after purchasing an additional 77 shares during the quarter. Dohj LLC’s holdings in Regeneron Pharmaceuticals were worth $373,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. UBS Group decreased their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a research report on Thursday, June 5th. Bank of America decreased their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $836.48.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $529.24 on Friday. The firm has a market cap of $57.14 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The company has a 50 day moving average of $563.19 and a 200-day moving average of $649.25. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the business earned $9.55 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.